Litcius/Paper detail

Discovery of small molecule Gαq/11 protein inhibitors against uveal melanoma

Ge Yang, Junjie Deng, Jianzheng Zhu, Lu Liu, Shumin Ouyang, Zhendong Song, Xiaolei Zhang, Xiao‐Feng Xiong

2022Acta Pharmaceutica Sinica B17 citationsDOIOpen Access PDF

Abstract

Constitutively activated G proteins caused by specific mutations mediate the development of multiple malignancies. The mutated Gαq/11 are perceived as oncogenic drivers in the vast majority of uveal melanoma (UM) cases, making directly targeting Gαq/11 to be a promising strategy for combating UM. Herein, we report the optimization of imidazopiperazine derivatives as Gαq/11 inhibitors, and identified GQ262 with improved Gαq/11 inhibitory activity and drug-like properties. GQ262 efficiently blocked UM cell proliferation and migration in vitro. Analysis of the apoptosis-related proteins, extracellular signal-regulated kinase (ERK), and yes-associated protein (YAP) demonstrated that GQ262 distinctly induced UM cells apoptosis and disrupted the downstream effectors by targeting Gαq/11 directly. Significantly, GQ262 showed outstanding antitumor efficacy in vivo with good safety at the testing dose. Collectively, our findings along with the favorable pharmacokinetics of GQ262 revealed that directly targeting Gαq/11 may be an efficient strategy against uveal melanoma.

Topics & Concepts

MelanomaEffectorMAPK/ERK pathwayApoptosisCancer researchSmall moleculeKinaseIn vitroIn vivoChemistryProtein kinase ASignal transductionCell biologyBiologyBiochemistryGeneticsOcular Oncology and TreatmentsMultiple Myeloma Research and TreatmentsRetinal Development and Disorders